Prominent cerebral veins on susceptibility-weighted angiography in acute meningoencephalitis.
CSF glucose level
acute meningoencephalitis
cerebral venous prominence
prominent cerebral veins
susceptibility-weighted angiography
Journal
Brain and behavior
ISSN: 2162-3279
Titre abrégé: Brain Behav
Pays: United States
ID NLM: 101570837
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
05
08
2023
received:
10
05
2023
accepted:
06
09
2023
medline:
13
11
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
ppublish
Résumé
We have commonly observed prominent cerebral veins on susceptibility-weighted angiography (SWAN) in acute meningoencephalitis. This study aimed to investigate the clinical significance of these findings. Cerebral veins on SWAN of 98 patients with acute meningoencephalitis diagnosed from February 2016 through October 2020 were classified into three groups according to the degree of venous prominence (mild, 23; moderate, 53; and prominent, 22). Clinical variables and laboratory findings were compared between these groups. The influence of variables on the prediction of prominent cerebral veins was measured by random forest (RF) and gradient boosting machine (GBM). As cerebral veins became more prominent, cerebrospinal fluid (CSF) glucose level decreased (69.61 ± 29.05 vs. 59.72 ± 22.57 vs. 48.36 ± 20.29 mg/dL, p = .01) and CSF protein level increased (100.73 ± 82.98 vs. 104.73 ± 70.99 vs. 159.12 ± 118.15 mg/dL, p = .03). The etiology of meningoencephalitis, neurological symptoms, and increased intracranial pressure (ICP) signs differed between groups (p < .05). RF and GBM demonstrated that CSF protein level was the variable with the highest power to predict the prominent cerebral vein (mean decrease in node impurity: 4.19, relative influence: 50.66). The presence of prominent cerebral veins on SWAN in acute meningoencephalitis was significantly associated with a low CSF glucose level and a high CSF protein level, as well as ICP. Thus, the visual grade of the cerebral veins on SWAN may be utilized for the management of patients with acute meningoencephalitis.
Sections du résumé
BACKGROUND AND PURPOSE
We have commonly observed prominent cerebral veins on susceptibility-weighted angiography (SWAN) in acute meningoencephalitis. This study aimed to investigate the clinical significance of these findings.
METHODS
Cerebral veins on SWAN of 98 patients with acute meningoencephalitis diagnosed from February 2016 through October 2020 were classified into three groups according to the degree of venous prominence (mild, 23; moderate, 53; and prominent, 22). Clinical variables and laboratory findings were compared between these groups. The influence of variables on the prediction of prominent cerebral veins was measured by random forest (RF) and gradient boosting machine (GBM).
RESULTS
As cerebral veins became more prominent, cerebrospinal fluid (CSF) glucose level decreased (69.61 ± 29.05 vs. 59.72 ± 22.57 vs. 48.36 ± 20.29 mg/dL, p = .01) and CSF protein level increased (100.73 ± 82.98 vs. 104.73 ± 70.99 vs. 159.12 ± 118.15 mg/dL, p = .03). The etiology of meningoencephalitis, neurological symptoms, and increased intracranial pressure (ICP) signs differed between groups (p < .05). RF and GBM demonstrated that CSF protein level was the variable with the highest power to predict the prominent cerebral vein (mean decrease in node impurity: 4.19, relative influence: 50.66).
CONCLUSION
The presence of prominent cerebral veins on SWAN in acute meningoencephalitis was significantly associated with a low CSF glucose level and a high CSF protein level, as well as ICP. Thus, the visual grade of the cerebral veins on SWAN may be utilized for the management of patients with acute meningoencephalitis.
Identifiants
pubmed: 37721542
doi: 10.1002/brb3.3255
pmc: PMC10636387
doi:
Substances chimiques
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3255Informations de copyright
© 2023 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
Références
Yonsei Med J. 2014 Sep;55(5):1231-7
pubmed: 25048479
Clin Neuroradiol. 2016 Jun;26(2):159-67
pubmed: 25245328
Neurology. 2013 Jul 9;81(2):199-200
pubmed: 23836944
J Neurol. 2011 May;258(5):932-4
pubmed: 21116823
J Infect Dis. 1992 Aug;166(2):350-8
pubmed: 1634806
J Neuroradiol. 2015 Oct;42(5):255-60
pubmed: 25451668
Brain Behav. 2023 Nov;13(11):e3255
pubmed: 37721542
Neuroradiol J. 2013 Oct;26(5):493-500
pubmed: 24199808
PLoS One. 2020 Jun 3;15(6):e0233992
pubmed: 32492059
Clin Microbiol Rev. 1993 Apr;6(2):118-36
pubmed: 8472245
Neurology. 1992 Apr;42(4):739-48
pubmed: 1565225
J Stroke Cerebrovasc Dis. 2013 Nov;22(8):1428-31
pubmed: 23410687
Eur J Radiol. 2014 Aug;83(8):1448-54
pubmed: 24882785
AJNR Am J Neuroradiol. 2014 Nov-Dec;35(11):2061-7
pubmed: 25012670
BMC Neurol. 2011 Oct 19;11:128
pubmed: 22011402
Curr Opin Neurol. 2014 Jun;27(3):361-8
pubmed: 24792345
PLoS One. 2016 Aug 03;11(8):e0160495
pubmed: 27486662
AJNR Am J Neuroradiol. 2014 Jun;35(6):1091-5
pubmed: 24371029
Neuroimaging Clin N Am. 2012 Nov;22(4):557-83
pubmed: 23122257
J Cereb Blood Flow Metab. 2016 Aug;36(8):1424-33
pubmed: 26661168
Neurology. 2020 Jun 16;94(24):e2577-e2580
pubmed: 32327494
N Engl J Med. 1992 Sep 17;327(12):864-72
pubmed: 1508247
J Neurosurg Anesthesiol. 2009 Jul;21(3):248-52
pubmed: 19543004
Cureus. 2021 Aug 28;13(8):e17529
pubmed: 34603897
J Neuroradiol. 2006 Dec;33(5):285-91
pubmed: 17213756
AJNR Am J Neuroradiol. 2004 Feb;25(2):274-9
pubmed: 14970030
CMAJ. 2019 May 13;191(19):E529-E534
pubmed: 31085562
Front Neurorobot. 2013 Dec 04;7:21
pubmed: 24409142
AJNR Am J Neuroradiol. 2009 Jan;30(1):19-30
pubmed: 19039041
Radiology. 2000 Jun;215(3):922-4
pubmed: 10831726
Magn Reson Imaging. 2014 Dec;32(10):1272-6
pubmed: 25131626
AJNR Am J Neuroradiol. 2009 Feb;30(2):232-52
pubmed: 19131406
J Neurol. 2012 Jul;259(7):1426-32
pubmed: 22186853
AJNR Am J Neuroradiol. 2008 Sep;29(8):e71
pubmed: 18372412
Neuroimaging Clin N Am. 2000 May;10(2):309-31
pubmed: 10775954
AJNR Am J Neuroradiol. 2008 Jan;29(1):9-17
pubmed: 17925363
Am J Emerg Med. 2014 Mar;32(3):263-6
pubmed: 24361137
Nat Rev Neurol. 2010 Nov;6(11):637-41
pubmed: 20842184
Neuroradiology. 2003 Sep;45(9):634-9
pubmed: 12908092
AJNR Am J Neuroradiol. 2016 Aug;37(8):1549-55
pubmed: 26988816
Scand J Infect Dis. 2009;41(5):348-54
pubmed: 19306157
Lancet. 2002 Jan 19;359(9302):228-30
pubmed: 11812561
Eur J Neurol. 2014 Nov;21(11):1411-8
pubmed: 25040846
J Magn Reson Imaging. 2009 May;29(5):1190-4
pubmed: 19388109
AJNR Am J Neuroradiol. 2011 Jan;32(1):E5-7
pubmed: 20075095